These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22695339)

  • 1. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Skaltsa K; Domènech B; Lomeña F; Pons F
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
    Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Duch J; Fuster D; Muñoz M; Fernández PL; Paredes P; Fontanillas M; Guzmán F; Rubí S; Lomeña FJ; Pons F
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1551-7. PubMed ID: 19326117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
    Hulikal N; Gajjala SR; Kalawat T; Kadiyala S; Kottu R
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):93-98. PubMed ID: 31983170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C; Niccoli Asabella A; De Luca R; Fanelli M; Caliandro C; Quartuccio N; Rubini D; Cistaro A; Montemurro S; Rubini G
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.
    Hyun SH; Ahn HK; Park YH; Im YH; Kil WH; Lee JE; Nam SJ; Cho EY; Choi JY
    Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer.
    Yoon HJ; Kim SK; Kim TS; Im HJ; Lee ES; Kim HC; Park JW; Chang HJ; Choi HS; Kim DY; Oh JH
    Clin Nucl Med; 2013 Jan; 38(1):7-12. PubMed ID: 23242038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
    García García-Esquinas M; García-Sáenz JA; Arrazola García J; Enrique Fuentes Ferrer M; Furió V; Rodriguez Rey C; Román JM; Carreras Delgado JL
    Q J Nucl Med Mol Imaging; 2014 Mar; 58(1):66-73. PubMed ID: 24104854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.